HER2, HER3 and TROP2: An Update on Novel Treatments for Key Targets

Pre-registration is now closed. We welcome you to register on-site by coming to the Sheraton New Orleans, 500 Canal Street, Grand Ballroom. Remember to bring your AACR badge to expedite your registration.


Clinical Care Options, LLC is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. Additionally, in accordance with AACR’s COVID-19 protocols, all in-person learners will be asked to wear a mask and present their AACR conference badge -OR- proof of vaccination AND Government-issued ID to gain admittance to HER2, HER3 and TROP2: An Update on Novel Treatments for Key Targets.

For more information on AACR’s vaccination and mask requirements, please visit: AACR’s website.

*If you do not have your vaccination record card, find out other ways to verify you have been vaccinated.

This symposium is sponsored by and supported by a grant from AstraZeneca and Daiichi Sankyo, Inc. This is not an official program of the American Association for Cancer Research Annual Meeting.


Welcome and Introduction

Antibody–Drug Conjugates in Lung Cancer
Sandip P. Patel, MD

Focus on HER2 and HER3 in Gastrointestinal Cancers
Yelena Y. Janjigian, MD

Targeting HER2, HER3, and TROP2 in Breast Cancer
Aditya Bardia, MD, MPH

Audience Question and Answer Session


Date / Time
Event Details


Program Director
Aditya Bardia, MD, MPH

Director, Breast Cancer Research
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

Yelena Y. Janjigian, MD

Associate Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Sandip P. Patel, MD

Division of Hematology and Medical Oncology
UC San Diego Moores Cancer Center
La Jolla, California

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to facilitate understanding and integration into clinical practice of the most relevant data on biomarker-guided, targeted treatment of various HER2-, HER3-, and TROP2-altered metastatic cancers, including breast, gastrointestinal, and lung.

Target Audience
This program is intended for oncologists and other healthcare professionals who care for patients with breast, gastrointestinal, and lung cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review the most recent evidence-based guidelines and expert recommendations for assessing HER2, HER3, and TROP2 in the metastatic setting for breast, gastrointestinal, and lung cancers
  • Appraise the latest available clinical data for established and emerging HER2-, HER3-, and TROP2-targeted therapies in breast, gastrointestinal, and lung cancers
  • Implement best practices for HER2, HER3, and TROP2 diagnostic testing and interpretation to guide integration of the latest targeted therapies into individualized treatment plans
  • Identify patients eligible to enroll on important ongoing clinical trials based evaluating novel HER2-, HER3-, and TROP2-targeted therapies in breast, gastrointestinal, and lung cancers


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.